Skip to main content

REVIEW article

Front. Cell Dev. Biol.
Sec. Signaling
Volume 12 - 2024 | doi: 10.3389/fcell.2024.1462808
This article is part of the Research Topic Revolutionizing Cancer Treatment: Navigating the Intricate Landscape of Cellular Signaling Networks View all 8 articles

A stumbling block in pancreatic cancer treatment: drug resistance signaling networks

Provisionally accepted
Jinming Liu Jinming Liu 1Biao Zhang Biao Zhang 1Bingqian Huang Bingqian Huang 2Kexin Zhang Kexin Zhang 1*Fujia Guo Fujia Guo 1*Zhizhou Wang Zhizhou Wang 1*Dong Shang Dong Shang 1*
  • 1 Dalian Medical University, Dalian, China
  • 2 Westlake University, Hangzhou, Zhejiang, China

The final, formatted version of the article will be published soon.

    The primary node molecules in the cell signaling network in cancer tissues are maladjusted and mutated in comparison to normal tissues, which promotes the occurrence and progression of cancer. Pancreatic cancer (PC) is a highly fatal cancer with increasing incidence and low five-year survival rates. Currently, there are several therapies that target cell signaling networks in PC. However, PC is a "cold tumor" with a unique immunosuppressive tumor microenvironment (poor effector T cell infiltration, low antigen specificity), and targeting a single gene or pathway is basically ineffective in clinical practice. Targeted matrix therapy, targeted metabolic therapy, targeted mutant gene therapy, immunosuppressive therapy, cancer vaccines, and other emerging therapies have shown great therapeutic potential, but results have been disappointing. Therefore, we summarize the identified and potential drug-resistant cell signaling networks aimed at overcoming barriers to existing PC therapies.

    Keywords: Pancreatic Cancer, signaling network, Drug Resistance, Matrix, gemcitabine

    Received: 10 Jul 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Liu, Zhang, Huang, Zhang, Guo, Wang and Shang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kexin Zhang, Dalian Medical University, Dalian, China
    Fujia Guo, Dalian Medical University, Dalian, China
    Zhizhou Wang, Dalian Medical University, Dalian, China
    Dong Shang, Dalian Medical University, Dalian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.